Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
05 01 2021
Historique:
received: 16 12 2019
accepted: 23 03 2020
pubmed: 24 6 2020
medline: 20 4 2021
entrez: 24 6 2020
Statut: ppublish

Résumé

Electronic patient-reported outcomes (ePROs) transmitted digitally allow patients to communicate with their clinicians and track the activity of chronic diseases, such as RA. Several ePRO smartphone apps have been developed in rheumatology, yet few data have been reported regarding patient adherence. We developed a PRO app for RA and assessed adherence over 6 months. We developed an app to deliver daily assessments to participants (RA App v.1.0). The app was tested as part of a randomized controlled trial examining potential clinical benefits. The current analyses focus on the adherence to the ePRO app for patients randomized to receive the app. We recruited RA patients from an academic rheumatology practice in the USA. Patients randomized to receive the app received daily notifications regarding ePROs. We examined adherence to the PRO questionnaires over the 6-month study and examined factors related to adherence. Seventy-eight patients received the app and have data included in these analyses: 63 (80.7%) were female, mean age was 55.2 years, 71% had attended college or beyond, and the mean Clinical Disease Activity Index at baseline was 9.7 (low disease activity). Median adherence to the daily questions was 79% (interquartile range 48-90%). Significant predictors of increased adherence were age ≥65 (P = 0.03) and low baseline Clinical Disease Activity Index (P = 0.02). We developed and tested an ePRO app for RA over a 6-month study. Adherence to the app was strong. There was correlation between older age and better disease control and increased adherence. ClinicalTrials.gov, https://clinicaltrials.gov/, NCT02822521.

Identifiants

pubmed: 32572490
pii: 5861028
doi: 10.1093/rheumatology/keaa202
doi:

Banques de données

ClinicalTrials.gov
['NCT02822521']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108-112

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Josh Colls (J)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Yvonne C Lee (YC)

Division of Rheumatology, Northwestern University Medical Center, Chicago, IL, USA.

Chang Xu (C)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Cassandra Corrigan (C)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Fengxin Lu (F)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Georgia Marquez-Grap (G)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Meredith Murray (M)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Dong H Suh (DH)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Daniel H Solomon (DH)

Division of Rheumatology, Brigham and Women's Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH